Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1709 details
Primary information
ID16196
Therapeutic IDTh1709
Protein NameKB001
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionKB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
Indication/DiseaseFor the treatment of infections caused by multi-drug resistant Pseudomonas aeruginosa.
PharmacodynamicsKaloBios is developing KB001, a PEGylated engineered human Fab' fragment for the prevention and treatment of Pseudomonas aeruginosa infections. The Fab' fragment is specific for the PcrV antigen, an essential component of the Type III secretion system, a key virulence factor with multiple roles in both infection and pathogenesis. KB001 shows potent activity in mouse models of pulmonary infection, reducing mortality and leading to effective clearance of bacteria from infected lungs. This molecule therefore represents an attractive candidate for clinical evaluation in the prevention or treatment of Pseudomonas infection in Cystic Fibrosis, pneumonia, and other indications.
Mechanism of ActionKB001 targets and neutralizes the PcrV protein of the Type III secretion system of the Pseudomonas bacterium, which directly inhibits its toxic effects. This mechanism of action is different from that of other antibiotics and represents a new approach in the treatment of bacterial infections.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetPcrV
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA